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BACKGROUND: Studies on peripheral benzodiazepine
receptor function have yielded a diverse list of
activities of which the anti-inflammatory effects
need to be further examined.
Aims: To evaluate the role of steroids, nitric oxide
and adenosine-deaminase in the anti-inflammatory
effect of PK11195.
Methods: Pleurisy was induced by intrapleural injec-
tion of carrageenan in mice pre-treated or not with
PK11195. Leukocytes, exudation, adenosine-deami-
nase (ADA) activity and nitric oxide (NO) level were
measured. Steroid involvement was evaluated by pre-
treatment with D,L-aminogluthetimide before
PK11195.
Results: Leukocytes, exudation and NO levels were
reduced by PK11195 in the early (4 h) phase. In the
late (48 h) phase, PK11195 decreased leukocytes and
ADA activity. D,L-aminogluthetimide reversed the
effect of PK11195 on exudate (4 h), as well as total
and differential leukocytes and NO levels (48 h).
Conclusions: Steroids, NO and ADA are implicated in
the anti-inflammatory action of PK11195.
Key words: PK11195, Pleurisy, Nitric oxide, Steroid Synth-
esis
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Introduction
The peripheral benzodiazepine receptor (PBR) is
an 18 kDa protein localised on the mitochondrial
outer membrane, where it is associated with at least
two other proteins: the voltage-dependent
anion channel protein, and the adenine nucleotide
carrier.
1,2 PK11195 [1-(2-chlorophenyl)-N-methyl-N-
(1-methylprolyl)-3-isoquinoline carboxamide] is
one of the most widely studied specific ligands for
the PBR. Only the 18 kDa subunit carries PK11195
binding domains.
3 The PBR is expressed in
many tissues and abundantly in classical steroid-
producing cells.
4,5 PBR ligands stimulate steroid
synthesis not only in endocrine tissues such
as adrenal glands, placenta, testes and ovaries,
but also in the liver, glia and Schwann cells
by enhancing the translocation of cholesterol
from outer to inner mitochondrial membranes,
the rate-limiting step in steroidogenesis.
6 12
Furthermore, the presence of PBRs in other
tissues in which steroidogenesis occurs, such as the
pancreas and the heart, suggests a role for these
receptors in steroid biosynthesis in different parts of
the body.
13,14
The PBR is widely distributed in the immune
system organs such as the spleen, thymus, intestine
and lymph nodes and in various types of human
blood cells,
15,16 presupposing an involvement of this
receptor in inflammatory and immune processes.
In a previous study, it was demonstrated that a
long pre-treatment time (24 h) with PK11195 had an
inhibitory effect on neutrophil influx, without inhibi-
tion of exudation in the inflammatory response 4 h
after carrageenan injection in a model of mouse
pleurisy.
17 Here, we report that a shorter pre-treat-
ment time (1 h) with PK11195 affects pleural exudate
formation and cellular infiltration in both early (4 h)
and late (48 h) inflammatory phases of carrageenan-
induced pleurisy in mice. The participation of ster-
oids in these anti-inflammatory PK11195 effects was
examined by using D,L-aminogluthetimide, a potent
inhibitor of P450scc, the enzyme responsible for the
transformation of cholesterol into pregnenolone.
18
Adenosine has signaling, cytoprotective and anti-
inflammatory roles depending on the receptor sub-
type and the levels of adenosine available.
19 Thus,
the subsequent interaction of adenosine with adeno-
sine type 2 receptors may inhibit, among others, the
expression of CD11b/CD18 molecules in leukocytes
that promote and facilitate cell migration.
20 In air-
ways, A2A receptors are present on many immunoin-
flammatory cells. Moreover, these receptors are
implicated in the suppression of degranulation of
neutrophils, mast cells, monocytes and T
lymphocytes.
21 23 Adenosine-deaminase (ADA) is
an enzyme that controls the concentration of adeno-
sine in organs and cells. ADA activity is significantly
increased in pleurisy induced by carrageenan.
24
Several studies have shown that ADA is able to
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93suppress the effects of the released adenosine.
25 On
the other hand, nitric oxide (NO) seems to play an
important role in the carrageenan-induced inflamma-
tory response. Thus, the lack of NO generation due to
the absence of inducible nitric oxide synthase (iNOS)
expression produces a significant reduction of the
pleural exudate and the number of emigrated
polymorphonuclear cells in carrageenan-induced
pleurisy.
26
Therefore, to better understand the mechanisms of
the observed anti-inflammatory effect of PK11195, we
analysed whether this involves steroid synthesis as
the underlying mechanism and the regulation of
adenosine and nitric oxide production in the carra-
geenan-induced pleurisy model.
Methods
The experiments were performed with the approval
of the Committee for the Use of Animals in Experi-
ments of the Universidade Federal de Santa Catarina
(Brazil).
Animals
Non-fasted adult Swiss mice of both sexes (18 /22
g; n /4 /6), aged 1 month, were used throughout
the experiments. They were housed in accordance
with institutional animal care requirements
(temperature 219 /28C, under a light/dark cycle of
12 h) and fed freely on standard rodent chow and
water.
Drugs
PK11195 from Sanofi-Synthe ´labo Recherche
(Labe `ge ´, France) was dissolved in absolute ethanol
and diluted with phosphate-buffered saline (PBS) to
the appropriate concentrations. The maximum
concentration of ethanol injected into the animal
was 1%. The vehicle utilised in control animals was
1% ethanol in PBS. D,L-Aminoglutethimide, carragee-
nan (degree IV), sodium azide, o-dianisidine
2HCl (3,3?-dimethoxybenzidine), and human poly-
morphonuclear leukocyte myeloperoxidase were
purchased from Sigma (St Louis, MO, USA). The
D,L-aminoglutethimide was dissolved in dimethylsulf-
oxide (DMSO) and diluted in PBS to the appropriate
concentration. The maximum concentration
of DMSO injected into the animal was 10% and
the vehicle utilised in control animals was 10% DMSO
in PBS. Neither 1% ethanol nor 10% DMSO affected
the inflammatory parameters evaluated 4 and 48 h
after pleurisy induction. The other drugs were
purchased, stocked and diluted as indicated: heparin
(Liquemine†; Roche, Sa ˜o Paulo, SP, Brazil),
NaH2PO4/H2O, Na2HPO4/12H2O, NH3SO4, nitro-
prussiate (Montedison, Sa ˜o Paulo, SP, Brazil),
adenosine (Fluka, Ronkonkoma, NY, USA), alkaline
buffer, hydrogen peroxide (30%), disodium N-hydro-
gen phosphate-12-hydrated, sulfanilic acid,
N-(1-naphyl)-ethylenodiamine dihydroxide, zinc-sul-
fate-7-hydrated, sodium phosphate, formamide
(Merck, Sa ˜o Paulo, SP, Brazil), ammonium formate
(Riedel-de Ha ¨en, Seelze, Germany), phenol (Biotech,
Sa ˜o Paulo, SP, Brazil). NaCl (0.9%), Evans Blue
and May /Grunwald /Giemsa dyes from different
commercial sources. PBS (Merck) was previously
prepared and maintained in the refrigerator. All drugs
were kept in siliconised plastic tubes at  /208C. On
the day of the experiments, the drugs were diluted to
the desired concentration with NaCl (0.9%) at room
temperature.
Experimental design
Carrageenan-induced pleurisy
As previously described,
27,28 pleurisy was induced by
a single intrapleural injection of 0.1 ml of carrageenan
(1%). Since the pleurisy caused by carrageenan
exhibits a biphasic response (4 and 48 h), these two
interval points were chosen to analyse the studied
parameters.
After killing the animals with an overdose of
ether, the thorax was opened and the pleural cavity
was washed with 1.0 ml of sterile PBS containing
heparin (20 IU/ml). Several samples of the
pleural lavage were collected for further determina-
tions of ADA activity,
29 exudate levels and
nitric oxide concentrations,
30 as well as total
and differential leukocyte contents. Total leukocytes
were performed on an automatic counting machine
(Beckman Coulter Inc., Brea, CA, USA), while cytos-
pin preparations of pleural wash were stained with
May /Grunwald /Giemsa for the differential count,
which was performed under an oil immersion
objective. All animals, except in the experiments
that analysed the enzyme activity or nitric
oxide levels, were previously challenged (1 h)
with a solution of Evans blue dye (25 mg/kg,
intravenously) in order to evaluate the degree
of exudation in the pleural cavity. A sample
(500 ml) of the fluid collected from the pleural
cavity was stored in a freezer ( /208C) to further
determine the concentration of Evans blue dye.
To this end, on the day of the experiments, a batch
of samples was thawed at room temperature and
the amount of dye was estimated by colorimetry
using an Elisa plate reader (Organon Teknika, Rose-
land, NJ, USA) at 600 nm, by interpolation from
a standard curve of Evans blue dye in the range of
0.01 /50 mg/ml.
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and cellular infiltration in carrageenan-induced
pleurisy
For dose /response studies, a group of animals was
treated 1 h before pleurisy induction with different
doses of PK11195 [0.01 /1.0 mg/kg, intraperitoneally
(i.p.)] or vehicle, and the inflammatory parameters
(leukocytes and exudation) were analysed 4 and 48 h
after carrageenan injection. In another set of experi-
ments, animals were pre-treated with one dose of
PK11195 (0.1 mg/kg, i.p.) or vehicle at different times
(0.5 /4 h) and the same inflammatory parameters
were evaluated 4 and 48 h after pleurisy induction.
For the time course of the later (48 h) phase, further
groups of animals were also treated with a single
injection (1 h) or with two injections of PK11195 (0.1
mg/kg, i.p.) or vehicle with a 12 h interval (the first
dose of PK11195 at 1 h before carrageenan and the
second dose 12 h after the first one).
Evaluation of the participation of steroids in the fluid
leakage and cell influx inhibition by PK11195
A group of animals was pre-treated (0.5 h) with 10
mg/kg of D,L-aminoglutethimide before 0.1 mg/kg
(i.p.) of PK11195 or vehicle, 1 h before carrageenan
administration. Thereafter, the pleural lavage samples
for the leukocytes counts and quantification of
exudation were evaluated 4 and 48 h after pleurisy
induction.
Determination of nitrate/nitrite concentrations
Mice treated with PK11195 or vehicle (0.1 mg/kg,
i.p.) 1 h prior to pleurisy induction or twice with a 12
h interval prior to pleurisy induction were utilised in
order to evaluate the action of PK11195 in the early (4
h) and late (48 h) phases of pleurisy upon nitrate/
nitrite levels, an indicator of NO synthesis in samples
of pleural lavage fluid.
Samples of the pleural lavage obtained from
control and treated animals that did not receive Evans
blue dye injection were collected, separated and
stored at  /208C, and the nitrate/nitrite levels were
determined by the Griess reaction as previously
described by Saleh et al.
30
Evaluation of the effect of PK11195 on the adenosine-
deaminase activity in pleurisy
ADA activity was measured 4 and 48 h after pleurisy
induction, according to the method developed by
Giusti and Galanti,
29 in samples of pleural lavage
from animals treated with 0.1 mg/kg of PK11195 (i.p.)
or vehicle given at 1 h or twice with a 12 h interval.
Using conventional reagents, the enzyme concentra-
tion was estimated by means of colorimetric mea-
surement (absorbency at 630 nm) on an Elisa plate
reader (Organon Teknika).
One unit of ADA is equivalent to the amount of
enzyme required to release 1 mmol of ammonia/min.
Results are expressed as units per litre. A detailed
description of this assay has been published pre-
viously by Fro ¨de and Medeiros.
24
Statistical analysis
Data are reported as the mean9 /standard error of the
mean. Differences between groups were determined
by analysis of variance complemented with Dunnett’s
and/or Student’s tests. pB/0.05 was considered
indicative of significance.
Results
Determination of the PK11195 effects on
leukocytes and exudation in carrageenan-
induced pleurisy
The time course studies indicated that only mice
treated with PK11195 0.5 and 1 h prior to the pleurisy
induction showed a significant inhibition of leuko-
cyte recruitment (percentage inhibition: 0.5 h, 339 /14
and 1 h, 329 /9, respectively; pB/0.05) (Fig. 1). This
effect was due to neutrophils influxes (percentage
inhibition: 0.5 h, 379 /15 and 1 h, 349 /10, respec-
tively; pB/0.05) (Fig. 1, inset). Furthermore, Fig. 1
also shows that only the treatment of animals with
PK11195 at 1 h caused a significant inhibition in
exudate levels (percentage inhibition, 379 /7; pB/
0.01).
In a previous study it was demonstrated that mice
treated with PK11195 (0.1 mg/kg) at 24 h prior to
pleurisy induction by carrageenan showed a signifi-
cant reduction in neutrophils, but no decrease in the
exudate levels.
17 Thus, to permit the study of the
action of PK11195 on both cell recruitment and
exudation we chose to pre-treat animals with
PK11195 at 1 h before pleurisy induction for the
dose /response studies.
Figure 2 shows that PK11195 (0.1 /1.0 mg/kg, i.p.)
administered 1 h before carrageenan inhibited signifi-
cantly the leukocyte influx in the early (4 h) phase of
pleurisy induction (percentage inhibition: 0.1 mg/kg,
329 /9; 0.5 mg/kg, 349 /7; and 1.0 mg/kg, 269 /9; p B/
0.05). The lowest dose of PK11195 (0.01 mg/kg) had
no significant effect on leukocyte influx. Figure 2
(inset) shows that thisinhibitoryeffectwas duemainly
to neutrophil influxes (percentage inhibition: 0.1 mg/
kg, 349 /10; 0.5 mg/kg, 339 /7; and 1.0 mg/kg, 259 /9;
pB/0.05).Furthermore,thedoseof0.5mg/kg,i.p.,1h
before was also effective in inhibiting mono-
nuclears (percentage inhibition, 559 /7; pB/0.05).
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observed with 0.01 mg/kg (percentage enhancement,
909 /3;pB/0.05).Ontheotherhand,only0.1mg/kgof
PK11195 produced a significant inhibition of exuda-
tion level (pB/0.01) (Fig. 2).
The time course studies (Fig. 3) carried out in the
later (48 h) phase, however, indicated that pre-
treatment with PK11195 at 2 and 4 h produces a
significant enhancement of leukocyte recruitment
(percentage enhancement: 2 h, 359 /6 and 4 h, 799 /
6; pB/0.01). Figure 3 (inset) shows that this effect
was due mainly to an enhancement of neutrophils
(percentage enhancement: 2 h, 3549 /10 and 4 h,
3919 /12; pB/0.01). However, mononuclear cells
were significantly fewer at 1, 2 and 4 h (percentage
reduction: 1 h, 559 /12; 2 h, 759 /3; and 4 h, 229 /8;
pB/0.01). No change in exudate levels was observed
with these pre-treatment times (data not shown). In
another group that received one first dose of
PK11195 at 1 h before carrageenan and a second
dose 12 h after the first one, a significant decrease in
the leukocyte infiltration was observed (percentage
decrease, 509 /3; pB/0.01) (Fig. 3) with no change in
exudate levels (data not shown). This leukocyte
inhibition was due to reduced mononuclear cell
influx (percentage inhibition, 749 /2; pB/0.01) (Fig.
3, inset).
Determination of the participation of steroids in
the fluid leakage and cell influx inhibition by
PK11195
Figure 4A shows that treatment of animals with D,L-
aminoglutethimide produced a reversal of the inhi-
FIG. 1. Effects of PK11195 administered 0.5 /4 h before carrageenan (Cg, 1%/cav.) on the early (4 h) phase of the mouse
pleurisy induced by Cg. Leukocytes and exudation levels. Inset: Mononuclear and neutrophil cells, under the same conditions.
C, Control responses in animals only treated with Cg. Each column represents the mean of four to six animals, and the vertical
bars represent the standard error of the mean. * pB/0.05 and ** pB/0.01.
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change in neutrophil influxes in the early (4 h) phase
of pleurisy (p B/0.01) (Fig. 4A, inset). In the later (48
h) phase, nevertheless, D,L-aminogluthetimide was
able to reverse not only the inhibitory effect of
PK11195 on mononuclear influx, but also caused
the accumulation of a volume of pleural exudate
(pB/0.01) (Fig. 4B and 4B, inset). Exudate levels and
leukocytes influx were not affected by D,L-amino-
gluthetimide without PK11195 (results not shown).
Evaluation of effect of PK11195 on the activities
of NO and ADA in pleurisy
The level of nitrate/nitrite in the lavage fluid from
animals treated with PK11195 significantly decreased
in the early (4 h) phase of pleurisy (percentage
inhibition, 479 /6; pB/0.01) (Table 1). However,
PK11195, was ineffective in inhibiting nitrate/nitrite
levels in the later (48 h) phase of pleurisy (Table 1).
PK11195, when administered in two doses of 0.1
mg/kg, i.p., with a 12 h interval, only inhibited the
ADA activity in the late (48 h) phase of pleurisy
(percentage inhibition, 589 /10; pB/0.01) (Table 1).
Discussion
Our results demonstrate that in a pleurisy model pre-
treatment of mice with PK11195 at 0.5 and 1 h before
carrageenan produced an important anti-inflamma-
tory action in the early (4 h) phase due mainly to
inhibition of neutrophil migration and fluid leakage
formation. On the late (48 h) phase, however, only
treatment with two injections of PK11195, a first 1 h
before carrageenan and a second 12 h after the first
one, was effective in inhibiting the leukocyte influx
due to mononuclear cells without changes in exu-
date. These results are in accordance with a previous
study, where it was observed that the anti-inflamma-
tory action of PK11195, in a model of acute inflam-
mation, disappeared 48 h after treatment.
31
It has been shown that PK11195 administered 24 h
before carrageenan in a pleurisy model exerted an
inhibitory effect on neutrophil influx, but no change
FIG. 2. Effects of different doses of PK11195 (0.01 /1.0 mg/kg, i.p.) administered 1 h prior to carrageenan (Cg, 1%/cav.), on the
early (4 h) phase of the mouse pleurisy induced by Cg. Leukocytes and exudation levels. Inset: Mononuclear and neutrophil
cells, under the same conditions. C, Control responses in animals only treated with Cg. Each column represents the mean of
four to six animals, and the vertical bars represent the standard error of the mean. * pB/0.05 and ** pB/0.01.
Involvement of steroids in anti-inflammatory effects of PK11195
Mediators of Inflammation Vol 13  2004 97in exudate levels in the early phase of pleurisy.
17
Thus, in this study, to characterise the role of the PBR
in both end points of the inflammatory process
(exudate formation and neutrophils infiltration) in
the early (4 h) phase of pleurisy, we chose to pre-
treat animals with PK11195 at 1 h before carrageenan.
As the single injections of PK11195 at all times of pre-
treatment analysed were not very effective in inhibit-
ing either total cell recruitment or exudate, animals
treated twice with PK11195 at 12 h time intervals
were utilised for the study of the mechanisms of
action of PK11195 in the late phase of pleurisy.
The mechanism responsible for the anti-inflamma-
tory action of PK11195 is not yet understood clearly.
PK11195 binding is increased in several pathological
situations where an inflammatory process is pre-
sent.
32 Pre-treatment with PK11195 prevents the
neurodegenerative effects, and increases PK11195
binding protein levels in the hippocampus of animals
treated with kainic acid.
33 The PBR density was
greatly increased in rat sciatic nerve degeneration,
and the administration of Ro5-4864 (i.p.) induced a
significant increase in pregnenolone levels in sciatic
nerve and plasma.
12 These results suggest that
glucocorticoid synthesis could be involved in PBR
ligands effects. Here, we confirmed the participation
of glucocorticoids in the anti-inflammatory action of
PBR activation by the utilisation of an inhibitor of
pregenenolone synthesis. Thus, D,L-aminoglutheti-
mide reversed the inhibitory effect of PK11195 on
exudation, but not on neutrophil influx to the mouse
pleural cavity in the early (4 h) phase of the
inflammatory response induced by carrageenan.
Furthermore, glucocorticoids are also implicated in
the inhibitory effect of PK11195 on mononuclear cell
influx observed in the late (48 h) phase of pleurisy.
Very few studies exist on the mediator implicated
in carrageenan-induced mouse pleurisy, but brady-
kinin (BK) and its degradative metabolite des-Arg9-
Bk seem to have an important role in fluid leakage
FIG. 3. Effects of PK11195 (0.1 mg/kg, i.p.), administered 1 /4 h before carrageenan (Cg, 1%/cav.) or twice with a 12 h interval,
on the late (48 h) phase of the mouse pleurisy induced by Cg. Leukocytes and exudation levels. Inset: Mononuclear and
neutrophil cells, under the same conditions. C, Control responses in animals only treated with Cg. Each column represents the
mean of four to six animals, and the vertical bars represent the standard error of the mean. ** pB/0.01.
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induced by carrageenan (Cg, 1%/cav.). The animals were pre-treated (0.5 h) with D,L-aminogluthetimide (10 mg/kg, i.p.) before
PK11195 (0.1 mg/kg, i.p.) and then mouse pleurisy was induced by Cg. (A) Leukocytes and exudation levels in the early (4 h)
phase of the inﬂammatory response. (B) Leukocytes and exudation levels in the late (48 h) phase of the inﬂammatory process.
Insets: Mononuclear and neutrophil cells, under the same conditions. C, Control responses in animals only treated with Cg.
Each column represents the mean of four to six animals, and the vertical bars represent the standard error of the mean. * pB/
0.05 and ** pB/0.01, Cg versus PK11195;
##pB/0.01, PK11195 versus D,L-aminoglutethimide plus PK 11195.
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bradykinin receptors have been identified, B1 and
B2.
34 The bradykinin B2 receptor is expressed con-
stitutively in several tissues and is considered to
mediate the majority of bradykinin effects such as
vasodilatation and increased vascular permeability.
BK stimulates the synthesis of IL-1, IL-2, and IL-6 from
lung strip explants, an effect susceptible to blockade
by a B2 BK receptor antagonist.
35 In lung fibroblasts
BK induces synthesis of IL-6 and IL-8 via the B2
receptor.
36 The bradykinin B1 receptor, however, is
not widely expressed in normal tissues, but is highly
inducible by inflammatory mediators as IL-1. The
interaction between interleukin-1 and B1 receptors
was clearly established in murine models of inflam-
mation where neutrophil accumulation induced by
interleukin-1 was due to up-regulation of B1 recep-
tors whose activation causes the release of substance
P and calcitonin gene-related peptide from sensory C
afferent fibres.
37,38 On the other hand, B1 receptor
agonists can mediate the induction of B1 receptors in
lung fibroblasts by a distinct but synergic mechanism
involving IL-1. Thus, the p38 mitogen-activated
proetin kinase pathway is implicated in B1 agonist-
promoted up-regulation of the B1 receptor. Nuclear
factor-kappa B (NF-kB) activation is very important
in the synergistic upregulation of B1 receptors,
but not in B1 agonist or IL-1b independent up-
regulation.
39
Regarding the early phase of the mouse pleurisy
model, a significant decrease in exudate formation
was observed in rats with a congenital deficiency in
plasma kininogen.
40,41 B2 receptor antagonists re-
duce the exudation rate and accumulation of pleural
fluid in pleurisy induced by carrageenan, and these
effects could be due to the inhibition of BK capacity
to up-regulate the production of cytokines such as IL-
1 and IL-6.
42 44 Thus, the B2 receptor seems to have
an important role in increased fluid leakage in the
early phase of pleurisy induced by carrageenan.
Neutrophil migration is absent in pleurisy induced
by carrageenan in mice that lack the B1 receptor,
whereas fluid leakage formation and mononuclear
cell infiltration are similar to those observed in wild-
type mice, showing that in this model neutrophil
recruitment is mediated mainly by B1 receptors, while
monocyte migration and fluid formation are not.
45
These data about bradykinin receptors in pleurisy,
when compared with the profile obtained in the
reversal of PK11195 action by D,L-aminogluthetimide
in the present study, suggest that there is a correlation
between effects of the PBR ligand mediated by
glucocorticoids and actions regulated by the B2
receptor, but not those regulated by the B1 receptor.
It has been reported that BK stimulates cytokine
gene expression through activation of the transcrip-
tion factor NF-kB via the B2 receptor and that BK-
induced cytokine production is inhibited by
corticosteroids.
46 48 Thus, it might be supposed that
PK11195 would inhibit fluid leakage and mono-
nuclear cell migration in pleurisy via stimulation of
steroid synthesis that, in turn, inhibits cytokine
production through inactivation of NF-kB. As the
inhibitory action of PBR ligands on neutrophils is not
via glucocorticoids, we can suppose that a PBR ligand
might have the capacity to inhibit the neutrophil
accumulation by a distinct mechanism that does not
involve inhibition of cytokines such as IL-1. For
example, the upregulation of the mechanism
mediated by B1 receptor-induced leukocyte traffick-
ing that involves both C fibres and mast cells, and that
probably occurs via substance P and histamine, is
known to involve the specific up-regulation and
rapid mobilisation of certain adhesion molecules for
neutrophils.
38 In addition, B1 agonist-promoted up-
regulation of the B1 receptor as described by Phagoo
et al.
39 could also be implicated.
Activation of B2 receptors in the murine model of
pleurisy concerns almost exclusively the migration of
mononuclear cells that is indirectly mediated by the
release of several inflammatory mediators (i.e. hista-
mine, NO and tachykinins), in addition to products
derived from the arachidonic acid pathway.
49 Many
of these inflammatory mediators exert their effect
partly by enhancing the release of pro-inflammatory
cytokines.
42,50 52 PBR ligands reduce the macro-
Table 1. Effect of the pre-treatment of the animals with PK11195 upon nitrate/nitrite and adenosine-deaminase levels on the
early (4 h) and late (48 h) phases of the inﬂammatory reaction induced by carrageenan in the mouse pleural cavity
Group Pleurisy 4 h Pleurisy 48 h
Nitrate/nitrite (mM) Adenosine-deaminase (IU/ml) Nitrate/nitrite (mM) Adenosine-deaminase (IU/ml)
Saline treated
a 299 /0.4 1.99 /0.2 2.99 /0.4 1.99 /0.2
Carrageenan treated
a 20.09 /1.3 5.09 /0.7 10.89 /0.8 6.99 /0.4
PK11195
b (0.1 mg/kg) 9.49 /1.1** 4.39 /1.2
PK11195
c (0.1 mg/kg)  /  / 9.29 /0.9 3.39 /0.5**
The parameters were analysed 4 and 48 h after the administration of either carrageenan or buffered-saline in the pleural cavity. Values
represent the mean9 /standard error of the mean (n /4 /6 animals per group). Statistical differences determined by analysis of variance,
complemented with Dunnett?s test are indicated: ** pB/0.01.
a Treatment given to the pleural cavity.
b Treatment given by i.p. route, 1 h before carrageenan.
c Treatment given by i.p. route with two doses of PK11195 of 0.1 mg/kg with a 12 h interval.
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53 In the pleurisy model, PK11195 caused a
marked inhibition of IL-6 and IL-13 in pleural
exudation. These data, together with the demonstra-
tion here that the inhibitory action of PK11195 on
mononuclear cell influx in the late phase of pleurisy
is dependent on glucocorticoids, suggest that this
action may be partly linked to the inhibition of the
release of pro-inflammatory cytokines.
PK11195 is not implicated in the modulation of this
fluid formation in the late phase of pleurisy. There is
little evidence for the participation of inflammatory
mediators in fluid formation in this phase but
prostaglandin I2 seems to have an essential role.
High quantities of cyclooxygenase-2 are expressed in
mesothelial cells in the late phase of pleurisy induced
by carrageenan, and this is not affected by dexa-
methasone.
54 The cyclooxygenase-2 expressed in
mesothelial cells may be the main factor responsible
for the formation of prostaglandin I2.
55 Thus, the
inability of glucocorticoids to inhibit cyclooxygenase-
2 expression in mesothelial cells could explain the
incapacity of PK11195 to decrease fluid leakage
formation in the late phase of pleurisy.
It was previously shown that the levels of nitrate/
nitrite are significantly elevated in both phases of
pleurisy while only in the early phase is NO produc-
tion inhibited by dexamethasone and a B2 receptor
antagonist.
30 Inhibitors of NOS activity reduce the
development of carrageenan-induced inflammation
and support a role for NO in the pathophysiology
associated with this model of inflammation.
56 59
Dexamethasone inhibits iNOS at the transcriptional
level.
60 Estrogens inhibit the increase of iNOS activity
in carrageenan-induced pleurisy.
61 We have now
showed that PK11195 significantly inhibits nitrate/
nitrite levels in the early phase of the pleurisy model
and that this action is mainly regulated by glucocor-
ticoids synthesis. Levels of nitrite/nitrate were un-
affected by PK11195 in the later phase.
Thus, the hypothesis that the anti-inflammatory
actions of PK11195 are correlated with its capacity to
inhibit NO levels can be proposed. As this effect was
reversed by D,L-aminogluthetimide, the PK11195-
induced decrease in NO levels could be due mainly
to the inhibition of iNOS (results not shown).
Rapid regulation of constitutive nitric oxide
synthase (cNOS) activity is exerted by estrogens
and glucocorticoids through activation of mitogen-
activated protein kinase and PI3K/Akt pathways.
62,63
NO produced by endothelial nitric oxide synthase
(eNOS) has previously been shown to be involved in
various pathophysiologic conditions, most notably in
the early phase of reperfusion of various organs
previously subjected to ischaemia.
64,65 The inability
of PK11195 to inhibit the exudation in the late (48 h)
phase of pleurisy suggest that cNOS could have an
important role in this phase.
Previous studies have shown that adenosine med-
iates the anti-inflammatory effects of other potent and
widely used anti-inflammatory agents such as metho-
trexate, sulfasalazine, aspirin and sodium salicylate,
but not glucocorticoids.
66 ADA, a marker of activated
mononuclear cells, is an enzyme that controls the
concentration of adenosine in organs and cells.
Several studies have shown that it is able to suppress
the effects of the released adenosine.
25 In the present
work, pre-treatment of the animals with PK11195
caused a reduction in the mononuclear cell pool in
association with a marked reduction of ADA activity
in the late phase of the inflammatory response
induced by carrageenan. Due to the fact that adeno-
sine mediates the anti-inflammatory effects of
PK11195 and glucocorticoids effects are not depen-
dent on adenosine, these data suggest a complemen-
tary mechanism of action of PK11195.
In summary, the present work presents evidence
that the anti-inflammatory action of PK11195 occurs
in part via glucocorticoids, but an adenosine-depen-
dent effect seems to be also implicated. We propose
that glucocorticoid synthesis might cause a decrease
in the actions of inflammatory mediators such as BK
due in part to inhibition of the release of pro-
inflammatory cytokines, but the validity of this
hypothetical mechanism needs to be confirmed.
Thus, this PBR ligand might be of pharmacological
interest as a potential anti-inflammatory agent based
on its capacity to act through several different
mechanisms.
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